Beta Bionics Reports 57% Q1 2026 Revenue Growth and Raised Full-Year Guidance
Beta Bionics, Inc. reported a 57% year-over-year revenue growth in Q1 2026, driven by new patient starts and high retention in its pharmacy-reimbursed user base. The company raised its full-year revenue guidance to $131 million–$136 million and increased its gross margin outlook to 57.5%–59.5%, citing the success of its pharmacy channel and manufacturing efficiencies.
Tickers: $BBNX
Topics: FDA Indication Gross Margin Expansion Market Expansion Pharmacy Channel Revenue Growth Sales Team Expansion